The current study combines two treatments for obstructive sleep apnea (OSA), oral appliances and supplemental inspired oxygen. The following aims will be tested: Aim 1. To determine whether supplemental inspired oxygen further reduces OSA severity (apnea-hypopnea index) in patients using an oral appliance. Aim 2. To determine whether baseline OSA phenotypes can predict the efficacy of oral appliances versus supplemental oxygen versus both treatments in combination. We will test whether responders to oral appliances have distinct pathophysiological characteristics compared with oxygen responders.
Pre-specified primary analysis for Aim 1 is the change in AHI with combination treatment versus oral appliance alone (%reduction versus placebo; including hypopnea events without desaturation/arousals). Aim 2 seeks to identify subgroups of patients that have the greatest reduction in AHI (responders) with each treatment (post-hoc). We will use baseline physiological measures of the four traits causing OSA (collapsibility, responsiveness, loop gain, arousal threshold) to determine which characteristics predict responses to each intervention (leave-one-out support vector machine modeling). Clinical measures of the same traits will be estimated from the placebo night to confirm that responses can be predicted with clinically-available data. We will also test whether responders to oral appliances have a greater response to oxygen than oral appliance non-responders (and vice-versa), to address whether responders to both treatments are similar or different.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
41
An oral appliance (dental mouthpiece) will be used to improve upper airway patency. Patients who do not have their own custom dental oral appliance (various brands, commonly Herbst/Somnomed) will be provided with a device (BluePro, BlueSom) for the duration of the study. Patients will also be administered sham (room air) at 4 L/min via nasal cannula.
Supplemental oxygen will be delivered at 4 L/min via nasal cannula to improve ventilatory control stability.
Both treatments will be administered simultaneously.
Subjects will not wear an oral appliance, and will be administered sham (room air) at 4 L/min via nasal cannula.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Sleep and Circadian Medicine Laboratory, BASE Facility, Monash University
Notting Hill, Victoria, Australia
Change in apnea hypopnea index (AHI), percent of baseline.
Primary test is difference between combination therapy and oral appliance
Time frame: Single night
Change in frequency of arousals, percent of baseline.
Primary test is difference between combination therapy and oral appliance
Time frame: Single night
Patient reported sleep quality (visual analog scale)
Primary test is difference between combination therapy and oral appliance
Time frame: Single night
Morning minus evening systolic blood pressure
Primary test is difference between combination therapy and oral appliance
Time frame: Single night
Morning minus evening diastolic blood pressure
Primary test is difference between combination therapy and oral appliance
Time frame: Single night
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.